Upsher-Smith Laboratories, Inc.
14905 23rd Avenue North
169 articles with Upsher-Smith Laboratories, Inc.
Strategic Acquisition of Tosymra™ (sumatriptan) Nasal Spray and Zembrace® SymTouch® (sumatriptan) Injection Further Expands and Diversifies Company's Portfolio
Dr. Reddy’s Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRA™ to Upsher-Smith Laboratories, LLC
Dr. Reddy’s Laboratories Limited, announces the closure of the transaction with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to the satisfactory completion of all customary closing conditions including the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended.
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that effective July 1, 2019 it will commercialize the KLOR-CON® (potassium chloride) and Potassium Chloride product families and will continue its role as manufacturer.
Dr. Reddy’s Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC
Dr. Reddy’s Laboratories Ltd. announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® 3 mg and TOSYMRA™ 10 mg, which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.
Upsher-Smith Laboratories Enters Into Agreement To Acquire Tosymra™ (sumatriptan nasal spray) And Zembrace® SymTouch® (sumatriptan injection)
Strategic Acquisition Diversifies Company's Portfolio and Provides New Options for Migraine Patients
Upsher-Smith Wins Two Prestigious DIANA Awards From HDA Including Overall Manufacturer Of The Year In Its Sales Category
The HDA presented 10 DIANA awards to outstanding pharmaceutical and consumer product manufacturers at its 2019 Business and Leadership Conference in Orlando on June 2-5, 2019.
Upsher-Smith Hosts National Alliance of State Pharmacy Associations/Pharmacists Mutual Leadership Conference
Two-day, Annual Event Took Place at its Maple Grove, Minnesota Headquarters
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Fluoxetine Tablets, USP, 10 and 20 mg. Upsher-Smith's product is AB-rated to the branded product, Prozac® (fluoxetine) tablets, USP*.
Upsher-Smith And The National Alliance Of State Pharmacy Associations (NASPA) Honor U.S. Pharmacists For Their Excellence In Innovation
Forty Awardees Chosen for Their Outstanding Role in Advancing Patient Care
Pharmaceutical Company Highlights Past Achievements, Future Endeavors
Qudexy® XR's Access Pathways® Program Platinum Pass™ Featured at Booth #415
Upsher-Smith Launches Generic Version Of Onfi® (clobazam), CIV In Tablet And Oral Suspension Dosage Forms
Upsher-Smith Laboratories, Inc. (Upsher-Smith) today announced the launch of Clobazam Tablets, CIV, 10 and 20 mg and Clobazam Oral Suspension, CIV, 2.5 mg/mL. Upsher-Smith's Clobazam products are AB-rated to the branded products, Onfi® (clobazam) tablets, CIV and Onfi® (clobazam) oral suspension, CIV.
Oklahoma Business Owner James Spoon Honored With 2018 Willard B. Simmons Independent Pharmacist Of The Year Award
Upsher-Smith Laboratories, Inc. (Upsher-Smith) is pleased to announce that James "Jim" Spoon DPh, an independent pharmacist with deep roots in his Sand Springs, Oklahoma community, is the winner of the 2018 National Community Pharmacist Association's (NCPA) Independent Pharmacist of the Year award.
Upsher-Smith Launches Generic Version of Lomotil® (diphenoxylate hydrochloride and atropine sulfate tablets)
Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced the launch of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP, 2.5 mg/0.025 mg. Upsher-Smith's product is an AA-rated generic version of the branded product, Lomotil® (diphenoxylate hydrochloride and atropine sulfate tablets)*.
Upsher-Smith Laboratories, LLC announced that it has added another product to its growing generic portfolio, supporting its commitment to expanding and diversifying its product offerings. The Company has launched four new products and two line extensions this year.
Upsher-Smith Enters Into Exclusive Marketing And Distribution Agreement For Six Ophthalmic/Otic ANDAs
Upsher-Smith Laboratories, LLC (Upsher-Smith) announced that it has entered into an exclusive agreement with a pharmaceutical partner to market and distribute a group of six ophthalmic and otic ANDA products.
Upsher-Smith Laboratories, LLC announced the launch of Doxazosin Tablets, USP, 1 mg, 2 mg, 4 mg and 8 mg.
Upsher-Smith Launches New Access Pathways® Platinum Pass At 2018 American Academy Of Neurology Annual Meeting
Upsher-Smith Laboratories, LLC announced that it will be featuring Platinum Pass, the latest addition to the Access Pathways® Program for Qudexy® XR (topiramate) extended-release capsules at the 70th Annual Meeting of the American Academy of Neurology (AAN), April 21-27, 2018, in Los Angeles, CA.
Upsher-Smith today announced that it has received FDA approval of its ANDA for Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg.
Upsher-Smith's Parent Company Completes Stake Transfer to Sumitomo Corporation in U.S. Generics Market
Upsher-Smith today reported that on January 3, 2018, its parent company, Sawai successfully completed the sale of a 20 percent stake in Sawai America, LLC to Sumitomo Corporation of Americas.